Brain Stimulation Devices Market To Reach $3.47 Billion By 2033

Deep Brain Stimulation Devices Market Growth & Trends

The global deep brain stimulation devices market size is expected to reach USD 3.47 billion by 2033, registering a CAGR of 10.88% from 2026 to 2033, according to a new report by Grand View Research, Inc. Growing awareness about deep brain stimulation therapy, a surge in the incidence of neurological disorders, and the introduction of technologically advanced productsdrive the growth of the market. An increase in FDA approvals for deep brain stimulation devices in clinical applications, such as tremors, severe obsessive-compulsive disorders, and dystonia, is further fueling the market growth. For instance, in December 2022, Nexstim Plc made a notable announcement regarding the sale of two NBT systems. These systems were acquired through Canadian Health Solutions (CHS), the company's distributor in Canada.

This development is expected to have a positive impact on the market's growth in the near future, signaling a growing demand for Nexstim's innovative solutions within the Canadian healthcare landscape. The incidence of neurological disorders such as epilepsy, Parkinson's disease, and depression is increasing globally, which is expected to positively impact the market growth. For instance, as per the Depression and Bipolar Support Alliance, about 17.3 million people in the U.S. are suffering from major depressive disorder. As a result, a large number of people suffering from such conditions & disorders is expected to boost the demand for DBS devices during the forecast period.

 Request a free sample copy or view report summary: Deep Brain Stimulation Devices Report

Deep Brain Stimulation Devices Market Report Highlights

• Based on product, the dual-channel segment is dominating the market in 2025. The single-channel deep brain stimulation device segment is expected to grow at the highest CAGR from 2026 to 2033.

• Based on end-use, the hospitals segment dominated the overall deep brain stimulation devices market in 2025. Ambulatory Surgery Centers (ASCs) segment expected to grow at a highest CAGR from 2026 to 2033.

• Basis on application, the Parkinson’s disease segment is dominating the market in 2025. Epilepsy segment is expected to grow at the highest CAGR from 2026 to 2033.

• North America dominated the deep brain stimulation devices market with a share of 50.21% in 2025. The deep brain stimulation devices market in U.S. is expected to dominate the market over the forecast period.

• Asia Pacific is expected to be the fastest growing region over the forecast period. Japan deep brain stimulation devices market in is witnessing a significant growth, driven by the increasing demand for innovative treatments for neurological disorders.

Deep Brain Stimulation Devices Market Segmentation

Grand View Research has segmented global deep brain stimulation devices market report on the basis of product, application, end-use and region:

Deep Brain Stimulation Devices Product Outlook (Revenue, USD Million, 2021 - 2033)

• Single Channel

• Dual Channel

Deep Brain Stimulation Devices Application Outlook (Revenue, USD Million, 2021 - 2033)

• Pain Management

• Epilepsy

• Essential Tremor

• Obsessive-compulsive Disorders (OCD)

• Depression

• Dystonia

• Parkinson’s Disease

• Others

Deep Brain Stimulation Devices End-use Outlook (Revenue, USD Million, 2021 - 2033)

• Hospitals

• Neurology Clinics

• Ambulatory Surgical Centers

• Research Centers

Deep Brain Stimulation Devices Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Sweden

  • Denmark

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Deep Brain Stimulation Devices Market

• Medtronic

• Boston Scientific Corporation

• Abbott

• Aleva Neurotherapeutics

• Newronika S.p.A.

• Beijing PINS Medical Co., Ltd.

• Neuronetics (Neurostar)